Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Study: Can ESG deliver Alpha? (I) Most hedge funds have not yet seized the responsible investment opportunity but this will change

Thursday, November 22, 2012
Opalesque Industry Update - Research piece authored by D. Michael Adams, Partner, Autumn Capital Partners, an investment consultancy firm based in London.


Investors are increasingly seeking strategies that deliver responsible investment (“RI”) values without sacrificing performance. Hedge funds, using more flexible strategies and techniques than traditional funds, have demonstrated an ability to deliver excess returns or alpha.

ESG data (Environmental, Social & Governance) is now widely available as a means to control risk and potentially add return while meeting RI criteria. Where are the opportunities and challenges for hedge funds to both capture RI market share and improve portfolio returns? This question is addressed in four parts:

I - Opportunities: Where the global RI and hedge fund markets intersect;
II - Challenges: Which RI issues are faced by hedge funds;
III - Strategies: How different strategies may meet RI criteria;
IV - Profiles: Organisations paving the way for more performance-driven RI.

Part I Full pdf report of Part I can be accessed here: www.autumncapital.com/media/uploaded/resources/ESG-white-paper-p1_final.pdf

Parts II, III and IV will be published in the coming months.

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its